EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Novel Dual-Targeting KRAS G12D /HDAC Peptide Inhibitor for the Treatment of Pancreatic Cancer

Qiaoxuan Zhang, Yifei Geng, Haitao Chen, Jiaping Ni, Lixia Guan, Dong Qing Zhai, Yuting Wang, Shengtao Xu, Miao-Miao Niu iD, Lufeng Zheng iD, Weiwei Hu

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c02435 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Qiaoxuan Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine/State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou Universi…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Histone Deacetylase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Double First Class University Plan, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer (PC) remains a highly lethal malignant tumor with limited effective treatment options. Histone deacetylase (HDAC) serves as a downstream signal of the Kirsten rat sarcoma (KRAS) signaling pathway in PC cells. In this study, we innovatively identified the first peptide inhibitor (KH-1) that simultaneously inhibited KRASG12D and HDAC through integrated virtual screening strategies based on pharmacophore screening and molecular docking. Microscale thermophoresis (MST) assays validated the nanomolar binding affinity of KH-1 for KRASG12D (Kd = 11.63 ± 0.71 nM) and HDAC2 (Kd = 20.17 ± 1.26 nM). KH-1 significantly inhibited human pancreatic cell proliferation, invasion, and migration. Flow cytometry showed that KH-1 significantly induced cell apoptosis and cell cycle arrest at the G0/G1 phase. In addition, KH-1 exerted obvious tumor growth inhibition in a xenograft model without significant organ toxicity. Overall, this work identifies KH-1 as a highly promising dual-targeting KRASG12D/HDAC peptide inhibitor for pancreatic cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Histone Deacetylase InhibitorsAntineoplastic AgentsPeptidesHistone Deacetylase 2HumansAnimalsCell ProliferationCell Line, TumorApoptosisMiceMolecular Docking SimulationMice, NudeCell MovementDrug DiscoveryXenograft Model Antitumor AssaysStructure-Activity Relationship

Substanzen

Proto-Oncogene Proteins p21(ras)Histone Deacetylase InhibitorsKRAS protein, humanAntineoplastic AgentsPeptidesHistone Deacetylase 2

Autor:innen und Institutionen

  • Department of Laboratory Medicine/State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medic…
  • Institute of Translational Medicine, China Pharmaceutical University, Nanjing 211198, China.
  • Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 211198, China.
  • School of Life Science and Technology, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 211198, China.
  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.

ORCID-Profile: Miao-Miao Niu, Lufeng Zheng

Förderung

  • Double First Class University Plan
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Outstanding Youth Program of the Lingang Laboratory
  • Guangdong Special Support Program Health and health talents List Project of Provincial Health Commission
  • “Double First-Class” University project of China Pharmaceutical University
  • "Young Talents Program" of Guangdong Academy of Traditional Chinese Medicine

Zitieren

APA

Zhang, Q., Geng, Y., Chen, H., Ni, J., Guan, L., Zhai, D. Q., Wang, Y., Xu, S., Niu, M. M., Zheng, L., & Hu, W. (2026). Discovery of a Novel Dual-Targeting KRAS G12D /HDAC Peptide Inhibitor for the Treatment of Pancreatic Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02435

Vancouver

Zhang Q, Geng Y, Chen H, Ni J, Guan L, Zhai DQ, et al. Discovery of a Novel Dual-Targeting KRAS G12D /HDAC Peptide Inhibitor for the Treatment of Pancreatic Cancer. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02435

BibTeX
@article{Zhang2026,
  author = {Zhang, Qiaoxuan and Geng, Yifei and Chen, Haitao and Ni, Jiaping and Guan, Lixia and Zhai, Dong Qing and Wang, Yuting and Xu, Shengtao and Niu, Miao-Miao and Zheng, Lufeng and Hu, Weiwei},
  title = {Discovery of a Novel Dual-Targeting KRAS G12D /HDAC Peptide Inhibitor for the Treatment of Pancreatic Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c02435}
}
Kostenlos starten →